论文部分内容阅读
目的 :分析老年急性髓细胞白血病 (AML)的临床特点和不同治疗方案的疗效。材料和方法 :年龄≥ 6 0岁的老年AML患者 5 3例 ,原发性AML4 4例和继发性AML 9例。AML分别采用亚常规标准剂量蒽环类药物或高三尖杉酯碱联合阿糖胞苷(Ara -C)或小剂量的高三尖杉酯碱和Ara -C作为诱导方案。结果 :发病时以发热和贫血症状最多见 ,以M5亚型常见 ,颅内出血是导致老年AML早期死亡的最常见的原因。急性髓细胞白血病 (AML)总的完全缓解 (CR)率 4 3.4 % ,亚标准剂量方案治疗AML的CR率明显高于小剂量HA的疗效 ,但继发性AML患者无 1例获CR。结论 :对原发性AML老年患者尽可能地采用亚标准剂量的诱导治疗方案。
Objective: To analyze the clinical features of elderly acute myeloid leukemia (AML) and the efficacy of different treatment regimens. MATERIALS AND METHODS: 53 elderly AML patients aged 60 years, 4 primary AML cases and 9 secondary AML cases. AML, respectively, using sub-routine standard-dose anthracycline or homoharringtonine combined with cytarabine (Ara-C) or small doses of homoharringtonine and Ara-C as an induction regimen. Results: The onset of fever and anemia symptoms most common to M5 subtype is common, intracranial hemorrhage is the leading cause of early death of elderly AML most common cause. The total complete remission (CR) rate was 4.34% in acute myeloid leukemia (AML). The CR rate of sub-standard dose regimen in treating AML was significantly higher than that of low dose HA, but none of the patients with secondary AML had CR. Conclusions: As far as possible, sub-standard dose induction therapy is used in elderly AML patients.